Prescription Glycopyrrolate Injection Recalled Due to Manufacturing Process Deviations
Accord Healthcare is recalling Glycopyrrolate Injection due to manufacturing process deviations found during FDA inspection. The recall involves 5,273 vials distributed across the United States, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall triggered by manufacturing process (CGMP) deviations identified during inspection. No illnesses or injuries have been reported. The recall represents a potential risk without confirmed harm, placing it in the High severity category.
Plain-English summary
Accord Healthcare, Inc. is recalling Glycopyrrolate Injection, USP (0.4 mg/2 mL), a prescription injectable drug. The recall involves 5,273 vials from three batches (R2200509, R2200507, R2200508), all expiring April 30, 2024.
The recall was initiated following an FDA inspection that identified deviations from Current Good Manufacturing Practice (CGMP). These manufacturing deviations created a potential risk that the drug may not meet required quality or safety standards.
The affected product was distributed throughout the United States, including Puerto Rico, and in Canada under NDC codes 16729-472-30 (individual vials) and 16729-472-08 (cartons).
Patients and healthcare facilities should check their inventory and records for the affected batch numbers. Those who may have received or administered doses from these batches should consult with their healthcare provider about appropriate follow-up actions.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Injectable / Prescription
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batches: R2200509
- Exp. Date 4/30/2024
- R2200507
- R2200508
UPCs (6)
- 0316729474054
- 0316729472302
- 0316729473316
- 0316729471633
- 316729472302
- 316729472081
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Oral Solution Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-02-04
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
FDA (Drugs) · 2023-06-14
- ModerateGlycopyrrolate injection recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighGlycopyrrolate Injection Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27